Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler from JMP Securities reiterated a Buy rating on the stock and has a $4.00 price target.
Jason Butler has given his Buy rating due to a combination of factors that highlight the growth potential of Esperion’s bempedoic acid franchise. The ongoing global expansion and development of bempedoic acid products are key drivers of this growth, with the company reporting revenues that exceeded expectations, largely due to a milestone payment from its Japanese partner, Otsuka. This positions Esperion well for further investment in U.S. commercial growth.
Additionally, despite U.S. net product sales falling slightly below estimates, the company experienced a 12% sequential demand growth, which is expected to align more closely with revenue in 2025. The increase in prescriber base and prescription volume, along with the successful marketing efforts in Europe and regulatory progress in Japan and Canada, further support the positive outlook. The development of new triple-combination products and potential pipeline expansions also contribute to the optimistic projection for the company’s future performance.
In another report released today, Needham also maintained a Buy rating on the stock with a $5.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESPR in relation to earlier this year.